76 related articles for article (PubMed ID: 7948149)
1. A phase I clinical trial to evaluate the safety and biological activity of HIV-IT (TAF) (HIV-1IIIBenv-transduced, autologous fibroblasts) in asymptomatic HIV-1 infected subjects.
Galpin JE; Casciato DA; Richards SB
Hum Gene Ther; 1994 Aug; 5(8):997-1017. PubMed ID: 7948149
[No Abstract] [Full Text] [Related]
2. An open label, phase I/II clinical trial to evaluate the safety and biological activity of HIV-IT (V) (HIV-1IIIBenv/rev retroviral vector) in HIV-1-infected subjects.
Haubrich R; McCutchan JA; Holdredge R; Heiner L; Merritt J; Merchant B
Hum Gene Ther; 1995 Jul; 6(7):941-55. PubMed ID: 7578412
[No Abstract] [Full Text] [Related]
3. Cytotoxic T lymphocyte and antibody responses generated in rhesus monkeys immunized with retroviral vector-transduced fibroblasts expressing human immunodeficiency virus type-1 IIIB ENV/REV proteins.
Laube LS; Burrascano M; Dejesus CE; Howard BD; Johnson MA; Lee WT; Lynn AE; Peters G; Ronlov GS; Townsend KS
Hum Gene Ther; 1994 Jul; 5(7):853-62. PubMed ID: 7981310
[TBL] [Abstract][Full Text] [Related]
4. A controlled, Phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA.
Wong-Staal F; Poeschla EM; Looney DJ
Hum Gene Ther; 1998 Nov; 9(16):2407-25. PubMed ID: 9829540
[TBL] [Abstract][Full Text] [Related]
5. Anti-HIV type 1 cytotoxic T lymphocyte effector activity and disease progression in the first 8 years of HIV type 1 infection of homosexual men.
Rinaldo CR; Beltz LA; Huang XL; Gupta P; Fan Z; Torpey DJ
AIDS Res Hum Retroviruses; 1995 Apr; 11(4):481-9. PubMed ID: 7632463
[TBL] [Abstract][Full Text] [Related]
6. A phase I/II pilot study of the safety of the adoptive transfer of syngeneic gene-modified cytotoxic T lymphocytes in HIV-infected identical twins.
Walker RE
Hum Gene Ther; 1996 Feb; 7(3):367-400. PubMed ID: 8835223
[No Abstract] [Full Text] [Related]
7. CTL cross reactivity between HIV strains.
Jolly D; Chada S; Townsend K; DeJesus C; Chang S; Weinhold K; Anderson CG; Lynn A; Bodner M; Barber J
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1369-71. PubMed ID: 1466957
[No Abstract] [Full Text] [Related]
8. A novel method for detection and ex vivo expansion of HIV type 1-specific cytolytic T lymphocytes.
Lubaki MN; Egan MA; Siliciano RF; Weinhold KJ; Bollinger RC
AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1427-31. PubMed ID: 7888197
[TBL] [Abstract][Full Text] [Related]
9. Human immunodeficiency virus type 1 envelope glycoprotein-specific cytotoxic T lymphocytes in simian-human immunodeficiency virus-infected rhesus monkeys.
Voss G; Li J; Manson K; Wyand M; Sodroski J; Letvin NL
Virology; 1995 Apr; 208(2):770-5. PubMed ID: 7747449
[TBL] [Abstract][Full Text] [Related]
10. Vaccine therapy using rgp 160 in early HIV infection.
Redfield R; Birx D; Ketter N; Polonis V; Johnson S; Davis C; Smith G; Oster C; Burke D
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1333. PubMed ID: 1361350
[No Abstract] [Full Text] [Related]
11. Detection of primary cytotoxic T lymphocytes specific for the envelope glycoprotein of HIV-1 by deletion of the env amino-terminal signal sequence.
McChesney M; Tanneau F; Regnault A; Sansonetti P; Montagnier L; Kieny MP; Rivière Y
Eur J Immunol; 1990 Jan; 20(1):215-20. PubMed ID: 2106442
[TBL] [Abstract][Full Text] [Related]
12. Equivalent recognition of HIV proteins, Env, Gag and Pol, by CD4+ and CD8+ cytotoxic T-lymphocytes.
Kundu SK; Merigan TC
AIDS; 1992 Jul; 6(7):643-9. PubMed ID: 1354446
[TBL] [Abstract][Full Text] [Related]
13. Clinical protocol. A phase 1 open-label clinical trial of the safety and tolerability of single escalating doses of autologous CD4 T cells transduced with VRX496 in HIV-positive subjects.
MacGregor RR
Hum Gene Ther; 2001 Nov; 12(16):2028-9. PubMed ID: 11727736
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of cytotoxic T cell responses to candidate HIV-1 vaccines in HIV-1-uninfected individuals.
McElrath MJ; Corey L; Greenberg PD
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S69-72. PubMed ID: 7865336
[TBL] [Abstract][Full Text] [Related]
15. Cytolytic T lymphocytes (CTLs) from HIV-1 subtype C-infected Indian patients recognize CTL epitopes from a conserved immunodominant region of HIV-1 Gag and Nef.
Thakar MR; Bhonge LS; Lakhashe SK; Shankarkumar U; Sane SS; Kulkarni SS; Mahajan BA; Paranjape RS
J Infect Dis; 2005 Sep; 192(5):749-59. PubMed ID: 16088824
[TBL] [Abstract][Full Text] [Related]
16. Epitope specificity of MHC restricted cytotoxic T lymphocytes induced by candidate HIV-1 vaccine.
Johnson RP; Hammond SA; Trocha A; Siliciano RF; Walker BD
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S73-5. PubMed ID: 7532425
[No Abstract] [Full Text] [Related]
17. Induction of anti-HIV-1 immune responses by retroviral vectors.
Jolly DJ; Warner JF
Biotechnol Ther; 1991; 2(1-2):179-93. PubMed ID: 1845120
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection.
Musey L; Hughes J; Schacker T; Shea T; Corey L; McElrath MJ
N Engl J Med; 1997 Oct; 337(18):1267-74. PubMed ID: 9345075
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of gp160 vaccinees in the hu-PBL-SCID mouse model.
Mosier DE; Gulizia RJ; MacIsaac P; Mathieson BJ; Smith G; Hu SL; Corey L; Greenberg P
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1387. PubMed ID: 1466962
[No Abstract] [Full Text] [Related]
20. Safety and immune responses to a DNA-based human immunodeficiency virus (HIV) type I env/rev vaccine in HIV-infected recipients: follow-up data.
MacGregor RR; Boyer JD; Ciccarelli RB; Ginsberg RS; Weiner DB
J Infect Dis; 2000 Jan; 181(1):406. PubMed ID: 10608800
[No Abstract] [Full Text] [Related]
[Next] [New Search]
